Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$636M |
| 2 |
UnitedHealth
UNH
|
+$635M |
| 3 |
Estee Lauder
EL
|
+$632M |
| 4 |
AbbVie
ABBV
|
+$466M |
| 5 |
PayPal
PYPL
|
+$451M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
O'Reilly Automotive
ORLY
|
+$559M |
| 2 |
SHPG
Shire pic
SHPG
|
+$464M |
| 3 |
Amazon
AMZN
|
+$458M |
| 4 |
Ulta Beauty
ULTA
|
+$439M |
| 5 |
Alibaba
BABA
|
+$397M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.96% |
| 2 | Healthcare | 15.31% |
| 3 | Consumer Discretionary | 14.83% |
| 4 | Communication Services | 12.99% |
| 5 | Financials | 11.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Byline Bancorp
BY
$1.76B
| $13.5M | 0.01% |
633,215
+67,035
| +12% | +$1.39M |
|
452
Ovintiv
OVV
$16.6B
| $13.3M | 0.01% |
+226,076
| New | +$11M |
|
453
Baker Hughes
BKR
$60.1B
| $13.3M | 0.01% |
+362,997
| New | +$12.9M |
|
|
EVHC
454
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $13.2M | 0.01% |
294,736
-63,752
| -18% | -$3.4M |
|
|
OA
455
DELISTED
Orbital ATK, Inc.
OA
| $13M | 0.01% |
97,831
-157,698
| -62% | -$17.3M |
|
|
PARA
456
DELISTED
Paramount Global Class B
PARA
| $12.9M | 0.01% |
+221,792
| New | +$14M |
|
457
Independence Realty Trust
IRT
$3.87B
| $12.7M | 0.01% |
+1,250,000
| New | +$12.6M |
|
458
Evolent Health
EVH
$429M
| $12.5M | 0.01% |
+704,007
| New | +$14.5M |
|
|
SEI
459
Solaris Energy Infrastructure
SEI
$3.22B
| $12.3M | 0.01% |
705,620
-59,147
| -8% | -$814K |
|
460
Freeport-McMoran
FCX
$90.2B
| $12.3M | 0.01% |
873,558
-49,461
| -5% | -$695K |
|
461
Ocular Therapeutix
OCUL
$1.89B
| $12.2M | 0.01% |
1,974,636
-10,860
| -0.5% | -$69.9K |
|
|
KYNB
462
Kyntra Bio
KYNB
$28.5M
| $12.1M | 0.01% |
+9,000
| New | +$9.48M |
|
463
NCS Multistage Holdings
NCSM
$121M
| $12.1M | 0.01% |
25,087
+2,154
| +9% | +$943K |
|
464
ProQR Therapeutics
PRQR
$244M
| $11.9M | 0.01% |
2,457,360
-15,248
| -0.6% | -$79.2K |
|
465
PUT
Insmed
INSM
$22.7B
| $11.9M | 0.01% |
380,000
+110,000
| +41% | +$2.1M |
|
466
Hain Celestial
HAIN
$46M
| $11.8M | 0.01% |
286,629
-1,683,781
| -85% | -$69.6M |
|
467
Commault Systems
CVLT
$6.19B
| $11.8M | 0.01% |
193,375
+450
| +0.2% | +$26.9K |
|
|
RICE
468
DELISTED
Rice Energy Inc.
RICE
| $11.7M | 0.01% |
402,961
-37,947
| -9% | -$1.04M |
|
|
CIM
469
Chimera Investment
CIM
$1.05B
| $11.4M | 0.01% |
201,324
| – | – |
|
|
SAGE
470
PUT
DELISTED
Sage Therapeutics
SAGE
| $11.4M | 0.01% |
183,000
-64,200
| -26% | -$5.04M |
|
471
e.l.f. Beauty
ELF
$4.95B
| $11.2M | 0.01% |
498,725
-218,069
| -30% | -$5.03M |
|
472
Syndax Pharmaceuticals
SNDX
$1.82B
| $11.1M | 0.01% |
951,898
-1,964
| -0.2% | -$24.1K |
|
473
Agios Pharmaceuticals
AGIO
$2.2B
| $11.1M | 0.01% |
166,065
-390
| -0.2% | -$23.4K |
|
474
MGP Ingredients
MGPI
$384M
| $10.9M | 0.01% |
+179,455
| New | +$10.3M |
|
475
BP
BP
$109B
| $10.8M | 0.01% |
+312,509
| New | +$9.93M |
|
Similar funds
Jennison Associates's Q3 2017 Portfolio in Review
As of Q3 2017, Jennison Associates held 727 positions worth $97.6B, up 3.6% from $94.3B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jennison Associates withdrew a net $3.38B in Q3 2017, closing 79 positions and reducing 330 holdings. Its most notable exit was O'Reilly Automotive, an estimated $559M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jennison Associates opened a new position in Estee Lauder worth $664M.
- Jennison Associates's largest Q3 2017 buy was Estee Lauder: 6,161,274 shares worth $664M.
- Jennison Associates added most to Alexion Pharmaceuticals in Q3 2017, an estimated $636M increase.
- Jennison Associates's biggest Q3 2017 reduction was Shire pic, cutting an estimated $464M.
- Jennison Associates fully exited O'Reilly Automotive in Q3 2017, selling an estimated $559M.
- Jennison Associates's ten largest holdings make up 28% of its $97.6B portfolio in Q3 2017.
- Jennison Associates opened 90 new positions and closed 79 in Q3 2017.
- Jennison Associates's portfolio value rose 3.6% quarter-over-quarter to $97.6B.
Based on Jennison Associates's 13F filing for Q3 2017, filed 3 Nov 2017.